[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-382643-105":59,"doc-detail-382643-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","her2-positive-gastric-cancer-the-role-of-immunotherapy-and-novel-therapeutic-strategies","HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies","","Gastric cancer remains an aggressive malignancy with rising global incidence and persistently high mortality. HER2 is overexpressed in roughly 10–20% of gastric cancers, and adding HER2-targeted therapy to standard care for metastatic disease has improved outcomes for this subgroup. Yet new options are required, especially as combinations of immunotherapy with HER2-directed treatments show synergistic effects in preclinical models. Emerging antibody–drug conjugates and other novel HER2-targeted agents are also generating clinical trial results, supporting continued evolution of treatment strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/her2-positive-gastric-cancer-the-role-of-immunotherapy-and-novel-therapeutic-strategies/382643/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/her2-positive-gastric-cancer-the-role-of-immunotherapy-and-novel-therapeutic-strategies/382643.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What proportion of gastric cancers overexpress HER2?","Question",{"text":112,"@type":113},"HER2 is overexpressed in approximately 10–20% of gastric cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are new treatments still needed for HER2-positive gastric cancer?",{"text":117,"@type":113},"Despite improved prognosis from HER2-targeted therapy in metastatic disease, gastric cancer still has high mortality and urgently requires additional strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"How does combining immunotherapy with HER2-targeted therapy affect research directions?",{"text":121,"@type":113},"Preclinical models show synergistic effects, providing the rationale for clinical trials of the combination in locally advanced and metastatic settings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},382643,1790910865,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nHER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies  \nAnna Pous 1,2, Luc½a Notario 1,2, Cinta Hierro 1,2, Laura Layos 1,2 and Cristina Bug²s 1,2, *  \nCitation: Pous, A.; Notario, L.;  \nHierro, C.; Layos, L.; Bugés, C.  \nHER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. Int. J. Mol. Sci. 2023, 24, 11403. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms241411403](10.3390/ijms241411403)  \nAcademic Editors: Paramjit S. Tappia and Bram Ramjiawan  \nReceived: 2 June 2023  \nRevised: 5 July 2023  \nAccepted: 7 July 2023  \nPublished: 13 July 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medical Oncology, Institut Catal d'Oncologia (ICO) Badalona, 08916 Badalona, Spain; [apousb@iconcologia.net](apousb@iconcologia.net) (A.P.); [lnotario@iconcologia.net](lnotario@iconcologia.net) (L.N.); [chierro@iconcologia.net](chierro@iconcologia.net) (C.H.); [llayos@iconcologia.net](llayos@iconcologia.net) (L.L.)  \n2 Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Spain  \n* Correspondence: [cbuges@iconcologia.net](cbuges@iconcologia.net)  \nAbstract: Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients. However, gastric cancer still has high mortality rates and urgently requires new treatment strategies. The combination of immunotherapy with HER2-targeted therapies has shown synergistic effects in preclinical models, this being the rationale behind exploring this combination in clinical trials in locally advanced and metastatic settings. Additionally, the irruption of antibody–drug conjugatesand other novel HER2-targeted agents has led to the development of numerous clinical trials showing promising results. This review presents the molecular mechanisms supporting the use of HER2-targeted drugs in combination with immunotherapy and provides an overview of the therapeutic scenario of HER2-positive disease. We focus on the role of immunotherapy but also summarize emerging therapies and combinations under clinical research that may change the standard treatment in HER-2 positive disease in the future.  \nKeywords: gastric cancer; HER2; immunotherapy; PD-1/PD-L1; antibody-drug conjugate; chemotherapy; trastuzumab; novel therapies; clinical trials  \n1. Introduction  \nGastric cancer is the fourth leading cause of cancer death worldwide and the fifth most common malignant tumor [1,2] .  \nIts occurrence varies markedly across different geographic regions [3], with Eastern Asian countries having the highest incidence rates, particularly China (accounting for half of all cases globally), Japan, and Korea [1] .  \nSeveral environmental and genetic factors are related to the development of gastric cancer [4,5] . Most cases are sporadic, but 5% to 10% have a family history of gastric cancer [6] . Some of the most relevant risk factors include diet (especially high-salt foods, low vitamin A and C diets, and smoked or cured foods), alcohol consumption, smoking, high body mass index, gastroesophageal reflux, and Helicobacter pylori and Epstein–Barr virus infections [5] .  \nAt early stages, gastric cancer is often asymptomatic, with symptoms usually appearing when the disease is in an advanced stage [7] . Common onset symptoms include non-specific weight loss, persistent abdominal pain, dysphagia, hematemesis, fati","cbCaibLlTaEza1qm","https://ap.wps.com/l/cbCaibLlTaEza1qm","pdf",1527746,21,"English","# Abstract\n# Keywords\n# Introduction\n## Epidemiology and Risk Factors\n## Clinical Presentation\n## Diagnosis and Staging\n## Classification of Gastric Cancer\n## Lauren Classification","[{\"question\":\"What proportion of gastric cancers overexpress HER2?\",\"answer\":\"HER2 is overexpressed in approximately 10–20% of gastric cancers.\"},{\"question\":\"Why are new treatments still needed for HER2-positive gastric cancer?\",\"answer\":\"Despite improved prognosis from HER2-targeted therapy in metastatic disease, gastric cancer still has high mortality and urgently requires additional strategies.\"},{\"question\":\"How does combining immunotherapy with HER2-targeted therapy affect research directions?\",\"answer\":\"Preclinical models show synergistic effects, providing the rationale for clinical trials of the combination in locally advanced and metastatic settings.\"}]","HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies | PDF",1790251476,53]